ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc.
Your view on ALXO
Overview
What the company does, where it operates, and who runs it.
About ALX Oncology Holdings Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason W. Lettmann
- Headquarters
- 323 Allerton Avenue, South San Francisco, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason W. Lettmann
- Headquarters
- 323 Allerton Avenue, South San Francisco, CA, US
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer.
Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.
The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics.
It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for ALX Oncology Holdings Inc. from FRC's valuation model, read against the market price. ALXO last traded at $1.12; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ALX Oncology Holdings Inc.. Starting points for ALX Oncology Holdings Inc.: EPS -$0.60, beta 0.40 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ALX Oncology Holdings Inc.. ALX Oncology Holdings Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ALX Oncology Holdings Inc.. Trailing twelve-month EPS for ALX Oncology Holdings Inc. stands at -$0.60. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$1.50
Median
$21.00
High
$38.00
Average target
Analyst Ratings
- Strong Buy0
- Buy6
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrJun 2020 | Next QtrSep 2020 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.32 | -$0.35 | -$0.56 | -$0.55 |
| Low estimate | -$0.32 | -$0.35 | -$0.60 | -$0.65 |
| High estimate | -$0.32 | -$0.35 | -$0.52 | -$0.49 |
| No. of analysts | 1 | 1 | 3 | 5 |
| Year-ago EPS | — | — | -$1.90 | — |
| Growth | — | — | +70.6% | — |
Revenue Estimate
| Revenue | Current QtrJun 2020 | Next QtrSep 2020 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $550000.00 | $250000.00 | $4.60M | $5.35M |
| Low estimate | $550000.00 | $250000.00 | $4.60M | $5.35M |
| High estimate | $550000.00 | $250000.00 | $4.60M | $5.35M |
| No. of analysts | 1 | 1 | 5 | 5 |
| Year-ago revenue | — | — | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ALX Oncology Holdings Inc.. ALX Oncology Holdings Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ALX Oncology Holdings Inc. valued side by side against its closest peers. ALX Oncology Holdings Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold ALX Oncology Holdings Inc., and how their positions are changing. At a $154.9M market value, institutional positions materially move ALX Oncology Holdings Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by ALX Oncology Holdings Inc. executives and directors. Shares of ALX Oncology Holdings Inc. have traded between $0.40 and $2.27 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ALX Oncology Holdings Inc.. Coverage tracks ALX Oncology Holdings Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of ALX Oncology Holdings Inc.